A new lawsuit accuses Johnson & Johnson and Procter & Gamble of deceiving consumers about decongestant cold medicines containing an ingredient that a unanimous U.S. Food and Drug Administration adv...

Roku's stock price has fallen 83% from its peak in 2021. The rocket-powered growth stock trades at just 3.7 times sales, which is comparable to many sleepy value investments.

Johnson & Johnson recently spun off its consumer health unit into a new company called Kenvue. The consumer health segment weighed on J&J's growth, but it could progress successfully as an independ...

A medical researcher has asked a court to throw out a lawsuit that Johnson & Johnson filed against her over her 2019 study on the links between cosmetic talc products and cancer, saying that her re...

J&J's (JNJ) erdafitinib is already marketed as Balversa in the United States for FGFR-altered metastatic UC. Balversa is approved by the FDA under the accelerated pathway.

Three of Johnson & Johnson's drugs could generate less revenue due to the Inflation Reduction Act. However, these three products are no longer part of Johnson & Johnson's long-term growth plans any...

You're familiar with its products, including Tylenol, Neutrogena, Listerine and Johnson's Baby Shampoo. Still, you may not be up to speed on Kenvue Inc. NYSE: KVUE and its status as a long-term div...

The decision to end the CTEPH study on J&J's (JNJ) Opsumit (macitentan) was made at the recommendation of the study's independent DMC, following a pre-planned interim analysis.

Kenvue, which was recently spun off from Johnson & Johnson, already pays an attractive dividend. The company supports that payout with a strong financial profile and durable business.

Johnson & Johnson said on Wednesday it has decided to stop a late-stage study testing its experimental drug to treat a type of hypertension.

Johnson & Johnson said on Wednesday its combination drug helped increase the duration of no progress in a type of non small-cell lung cancer in patients.

Many view the 30 stocks that comprise the Dow Jones Industrial Average as safe, solid “blue-chip” stocks that will never drop a great deal. For example, the business news company Kiplinger wrote: “...

Johnson & Johnson is a long-time healthcare leader with 61 straight years of dividend hikes. Visa and Mastercard have very little competition in their industry, and both still have growth potential.

Johnson & Johnson refreshed its financial guidance following its split from Kenvue. The healthcare behemoth offset most of the financial impact of the split because the exchange offer lowered its s...

Johnson & Johnson stock (NYSE: JNJ) has seen a 3% fall in a month, compared to a 2% fall for the broader S&P500 index.